MFAM
ANAB icon

Motley Fool Asset Management’s AnaptysBio ANAB Stock Holding History

Motley Fool Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12
Closed – – 224
2021
Q4 		$0 Buy
+12
New +$381 ﹤0.01% 334

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Motley Fool Asset Management's ANAB Position: Q1 2022 in Review

Motley Fool Asset Management sold out of AnaptysBio (ANAB) in Q1 2022, closing a stake of 12 shares.

Motley Fool Asset Management first reported a position in ANAB in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 131 funds tracked by Wall St. Rank hold ANAB as of Q1 2022.

  • Motley Fool Asset Management reported no remaining AnaptysBio position as of Q1 2022 after selling out during the quarter.
  • Motley Fool Asset Management sold 12 AnaptysBio shares in Q1 2022.
  • Motley Fool Asset Management first reported a position in AnaptysBio in Q4 2021 and held it in 1 quarter.
  • Motley Fool Asset Management's AnaptysBio position peaked at $0 in Q4 2021.
  • 131 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2022.

Based on Motley Fool Asset Management's 13F filing for Q1 2022, filed 4 May 2022.